MediciNova, Inc. (MNOV)
Largest Insider Buys in Sector
MNOV Stock Price History Chart
MNOV Stock Performance
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Insider Activity of MediciNova, Inc.
Over the last 12 months, insiders at MediciNova, Inc. have bought $0 and sold $0 worth of MediciNova, Inc. stock.
On average, over the past 5 years, insiders at MediciNova, Inc. have bought $69,240 and sold $25,615 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $7,240 was made by Matsuda Kazuko (Chief Medical Officer) on 2020‑03‑13.
List of Insider Buy and Sell Transactions, MediciNova, Inc.
| 2022-11-28 | Sale | Nagao Hideki | director | 6,754 0.0116% | $2.25 | $15,197 | -16.35% | |
| 2022-11-22 | Sale | Nagao Hideki | director | 218 0.0004% | $2.13 | $464 | +5.19% | |
| 2022-11-21 | Sale | Nagao Hideki | director | 5,365 0.0112% | $2.18 | $11,696 | +4.69% | |
| 2022-11-17 | Sale | Nagao Hideki | director | 309 0.0006% | $2.18 | $674 | +2.29% | |
| 2021-03-11 | Sale | Nagao Hideki | director | 2,354 0.0052% | $7.40 | $17,420 | -47.29% | |
| 2020-09-15 | Sale | Nagao Hideki | director | 1,000 0.0022% | $5.78 | $5,780 | -11.94% | |
| 2020-03-13 | Matsuda Kazuko | Chief Medical Officer | 2,000 0.0041% | $3.62 | $7,240 | +38.71% | ||
| 2020-03-12 | IWAKI YUICHI | President and CEO | 20,000 0.0451% | $3.10 | $62,000 | +78.59% | ||
| 2017-08-21 | Ishizaka Yoshio | director | 5,000 0.0148% | $5.17 | $25,850 | +71.53% | ||
| 2017-05-15 | Kobayashi Yutaka | director | 2,000 0.0056% | $5.60 | $11,200 | +15.24% | ||
| 2017-05-12 | Kobayashi Yutaka | director | 48,000 0.1421% | $5.62 | $269,760 | +20.44% | ||
| 2016-09-15 | Kobayashi Yutaka | director | 23,600 0.0662% | $6.44 | $151,984 | -10.96% | ||
| 2016-09-09 | Kobayashi Yutaka | director | 20,000 0.06% | $6.67 | $133,400 | -7.75% | ||
| 2016-07-05 | Sale | OBrien Geoffrey | Vice President | 6,600 0.0155% | $6.40 | $42,240 | -22.50% | |
| 2014-12-10 | Kobayashi Yutaka | director | 24,000 0.1054% | $3.54 | $84,960 | +4.48% | ||
| 2014-11-26 | Kobayashi Yutaka | director | 20,000 0.0812% | $3.07 | $61,400 | +11.78% | ||
| 2014-11-20 | Kobayashi Yutaka | director | 26,000 0.1112% | $3.19 | $82,940 | +13.23% | ||
| 2014-11-19 | Ishizaka Yoshio | director | 10,000 0.04% | $2.86 | $28,600 | +18.18% | ||
| 2014-09-11 | Kobayashi Yutaka | director | 20,000 0.084% | $2.95 | $59,000 | +22.68% | ||
| 2014-09-03 | Kobayashi Yutaka | director | 30,000 0.132% | $2.66 | $79,698 | +42.80% |
Insider Historical Profitability
| IWAKI YUICHI | President and CEO | 780683 1.5917% | $1.43 | 15 | 0 | +31.46% |
| Izumi Tatsuo | director | 600000 1.2233% | $1.43 | 5 | 1 | <0.0001% |
| Matsuda Kazuko | Chief Medical Officer | 111746 0.2278% | $1.43 | 1 | 0 | +38.71% |
| Kalafer Michael E | Chief Medical Officer | 31744 0.0647% | $1.43 | 1 | 0 | |
| Kobayashi Yutaka | director | 25000 0.051% | $1.43 | 9 | 0 | +12.44% |
| Ishizaka Yoshio | director | 10000 0.0204% | $1.43 | 2 | 0 | +44.86% |
| O'Toole David D | director | 5000 0.0102% | $1.43 | 1 | 0 | +8.62% |
| OBrien Geoffrey | Vice President | 5000 0.0102% | $1.43 | 0 | 1 | |
| COFFEE MICHAEL DENIS | CBO & Interim CFO | 4000 0.0082% | $1.43 | 1 | 0 | <0.0001% |
| Johnson Kirk William | Chief Scientific Officer | 1700 0.0035% | $1.43 | 1 | 0 | <0.0001% |
| Nagao Hideki | director | 0 0% | $1.43 | 0 | 6 | |
| Morris Arlene | director | 0 0% | $1.43 | 0 | 1 |
Institutional Investor Ownership
| Essex Woodlands Management Inc | $1.6M | 2.26 | 1.11M | 0% | +$0 | 0.47 | |
| BlackRock | $1.01M | 1.42 | 695,420 | -0.6% | -$6,121.91 | <0.0001 | |
| The Vanguard Group | $903,833.00 | 1.27 | 623,333 | 0% | +$0 | <0.0001 | |
| Citigroup | $649,538.00 | 0.91 | 447,957 | 0% | +$0 | <0.01 | |
| Geode Capital Management | $635,080.00 | 0.89 | 437,860 | +0.49% | +$3,085.04 | <0.0001 | |
| Renaissance Technologies | $334,000.00 | 0.47 | 230,400 | +32.34% | +$81,615.45 | <0.01 | |
| State Street | $227,937.00 | 0.32 | 157,198 | 0% | +$0 | <0.0001 | |
| Northern Trust | $222,537.00 | 0.31 | 153,474 | -0.05% | -$118.90 | <0.0001 | |
| Bank of America | $215,266.00 | 0.3 | 148,459 | -11.61% | -$28,275.06 | <0.0001 | |
| Bridgeway Capital Management | $210,463.00 | 0.3 | 145,147 | 0% | +$0 | <0.01 | |
| Dimensional Fund Advisors | $156,156.00 | 0.22 | 107,694 | -29.39% | -$65,012.07 | <0.0001 | |
| BNY Mellon | $139,449.00 | 0.2 | 96,172 | -19.79% | -$34,396.80 | <0.0001 | |
| Barclays | $121,000.00 | 0.17 | 83,200 | -8.87% | -$11,780.05 | <0.0001 | |
| Schonfeld Group | $61,190.00 | 0.09 | 42,200 | +1.44% | +$870.00 | <0.0001 | |
| JPMorgan Chase | $48,540.00 | 0.07 | 33,476 | -74.91% | -$144,937.05 | <0.0001 | |
| Millennium Management LLC | $43,570.00 | 0.06 | 30,048 | -17.43% | -$9,195.98 | <0.0001 | |
| Citadel Advisors LLC | $37,949.00 | 0.05 | 26,172 | New | +$37,949.00 | <0.0001 | |
| T. Rowe Price | $31,000.00 | 0.04 | 20,700 | 0% | +$0 | <0.0001 | |
| Bank Julius Baer Co Ltd Zurich | $27,550.00 | 0.04 | 19,000 | 0% | +$0 | <0.0001 | |
| Squarepoint Ops LLC | $21,541.00 | 0.03 | 14,856 | -1.94% | -$426.30 | <0.0001 | |
| Xtx Topco Ltd | $19,034.00 | 0.03 | 13,127 | New | +$19,034.00 | <0.01 | |
| Wealthtrust Axiom Llc | $18,125.00 | 0.03 | 12,500 | 0% | +$0 | 0.01 | |
| Jane Street Capital | $16,766.00 | 0.02 | 11,563 | -19.39% | -$4,033.82 | <0.0001 | |
| Tower Research Capital | $15,355.00 | 0.02 | 10,590 | +30.15% | +$3,556.73 | <0.0001 | |
| UBS | $3,642.00 | 0.01 | 2,512 | New | +$3,642.00 | <0.0001 | |
| Fidelity Investments | $1,742.00 | <0.01 | 1,202 | New | +$1,742.00 | <0.0001 | |
| Qube Research & Technologies | $1,567.00 | <0.01 | 1,081 | -60.17% | -$2,367.17 | <0.0001 | |
| Northwestern Mutual Wealth Management Co | $442.00 | <0.01 | 305 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | <0.01 | 380 | -55.24% | -$1,234.21 | <0.0001 | |
| Simplex Trading Llc | $0 | <0.01 | 441 | +102.29% | +$0 | <0.0001 | |
| Wells Fargo | $555.00 | <0.01 | 383 | +1.59% | +$8.70 | <0.0001 | |
| Group One Trading | $1.00 | <0.01 | 1 | New | +$1.00 | <0.0001 | |
| Morgan Stanley | $64.00 | <0.01 | 44 | 0% | +$0 | <0.0001 |